DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Schizophrenic Patients With Ziprasidone

Information source: Pfizer
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Ziprasidone (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.

Clinical Details

Official title: Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Summary of Schizophrenia

Summary of Metabolic Risk Factors

Summary of Most Frequently Used Concomitant Drug Treatments

Secondary outcome:

Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)

Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)

Positive and Negative Syndrome Scale (PANSS) - Positive Subscale

PANSS - Negative Subscale

PANSS - Composite Subscale

Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?"

Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?"

Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?"

Number of Participants Answering the Question "As a Result of Taking This Medication, do You Experience Any Side Effects at All?"

Number of Participants Answering the Question "How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?"

Number of Participants Answering the Question "To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?"

Number of Participants Answering the Question "To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?"

Number of Participants Answering the Question "To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?"

Number of Participants Answering the Question "How Easy or Difficult is it to Use the Medication in Its Current Form?"

Number of Participants Answering the Question "How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?"

Number of Participants Answering the Question "How Convenient or Inconvenient is it to Take the Medication as Instructed?"

Number of Participants Answering the Question "Overall, How Confident Are You That Taking This Medication is a Good Thing?"

Number of Participants Answering the Question "How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?"

Number of Participants Answering the Question "Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?"

Percent Change From Baseline to Final Visit in Body Weight

Detailed description: Sampling Method Details: Non-interventional study (subjects chosen by physician in accordance to their usual practice).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Usual clinical practice of physician

Exclusion Criteria:

- None

Locations and Contacts

Pfizer Investigational Site, Athens 12461, Greece

Pfizer Investigational Site, Chaidari 124 61, Greece

Pfizer Investigational Site, Chaidari 12461, Greece

Pfizer Investigational Site, Chaidari 12462, Greece

Pfizer Investigational Site, Corfu 49100, Greece

Pfizer Investigational Site, Crete 731-00, Greece

Pfizer Investigational Site, Giannitsa 58100, Greece

Pfizer Investigational Site, Haidari 12461, Greece

Pfizer Investigational Site, Kalamata 24100, Greece

Pfizer Investigational Site, Katerini 60100, Greece

Pfizer Investigational Site, Kozani 50100, Greece

Pfizer Investigational Site, Kozani, Greece

Pfizer Investigational Site, Lamia 35100, Greece

Pfizer Investigational Site, Larisa, Greece

Pfizer Investigational Site, Patra 26001, Greece

Pfizer Investigational Site, Patra 26000, Greece

Pfizer Investigational Site, Thessaloniki 564-29, Greece

Pfizer Investigational Site, Thessaloniki 56430, Greece

Pfizer Investigational Site, Thessaloniki 57010, Greece

Pfizer Investigational Site, Volos 38222, Greece

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: October 2007
Last updated: September 16, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017